A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects

Trial Profile

A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Ketoconazole; Moxifloxacin; Neratinib
  • Indications Bacterial infections; Breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2012 Company [Puma Biotechnology] added as trial association as reported by ClinicalTrials.gov.
    • 10 Oct 2010 Planned number of patients changed from 60 to 60.
    • 29 Jan 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top